Compare · ESTA vs STE
ESTA vs STE
Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESTA and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $21.75B, about 11.2x ESTA ($1.95B).
- Over the past year, ESTA is up 123.8% and STE is down 1.5% - ESTA leads by 125.3 points.
- ESTA has been more active in the news (7 items in the past 4 weeks vs 3 for STE).
- STE has more recent analyst coverage (16 ratings vs 13 for ESTA).
- Company
- Establishment Labs Holdings Inc.
- STERIS plc (Ireland)
- Price
- $66.24+1.69%
- $221.72-0.76%
- Market cap
- $1.95B
- $21.75B
- 1M return
- +11.16%
- -0.80%
- 1Y return
- +123.82%
- -1.52%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 7
- 3
- Recent ratings
- 13
- 16
Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest ESTA
- SEC Form DEFA14A filed by Establishment Labs Holdings Inc.
- Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6
- SEC Form 4 filed by Chacon Quiros Juan Jose
- SEC Form DEFA14A filed by Establishment Labs Holdings Inc.
- SEC Form DEF 14A filed by Establishment Labs Holdings Inc.
- Amendment: SEC Form 4 filed by Caldini Filippo
- Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market
- SEC Form 4 filed by Schutter Edward J
- SEC Form 4 filed by Gillin Leslie
- SEC Form 4 filed by Slotkin Bryan
Latest STE
- STERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026
- Teleflex Announces Governance Updates
- SEC Form 8-K filed by STERIS plc (Ireland)
- Amendment: SEC Form SCHEDULE 13G/A filed by STERIS plc (Ireland)
- Director Feldmann Cynthia L exercised 3,098 units of Ordinary Shares at a strike of $152.32 and sold $734,877 worth of Ordinary Shares (3,098 units at $237.21) (SEC Form 4)
- SEC Form 144 filed by STERIS plc (Ireland)
- SEC Form 10-Q filed by STERIS plc (Ireland)
- STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- STERIS Announces Financial Results for Fiscal 2026 Third Quarter
- STERIS Announces Dividend of $0.63 per share